journal article·2024-02

Chitosan and hyaluronic acid-based nanocarriers for advanced cancer therapy and intervention

Parul Rohtagi, Unnati Garg, Triveni, Neha Jain, Manisha Pandey, Mohd Cairul Iqbal Mohd Amin, Bapi Gorain, Pradeep Kumar

Publisher page

Abstract

Cancer has become a major public health issue leading to one of the foremost causes of morbidity and death in the world. Despite the current advances in diagnosis using modern technologies and treatment via surgery or chemo- and radio-therapies, severe side effects or after-effects limit the application of these treatment modalities. Novel drug delivery systems have shown the potential to deliver chemotherapeutics directly to cancer cells, thus minimizing unnecessary exposure to healthy cells. Concurrently, to circumvent difficulties associated with conventional deliveries of cancer therapeutics, natural polysaccharides have gained attention for the fabrication of such deliveries owing to biocompatibility, low toxicity, and biodegradability. It has been exhibited that natural polysaccharides can deliver high therapeutic concentrations of the entrapped drug to the target cells by sustained and targeted release. Considering the immense potential of natural polymers, the present work focuses on naturally generated biopolymer carriers based on chitosan and hyaluronic acid. This review delineated on the role of chitosan and its derivation from renewable resources as a biocompatible, biodegradable, nonimmunogenic material with notable antitumor activity as a drug delivery carrier in oncotherapy. Moreover, hyaluronic acid, itself by its structure or when linked with other molecules contributes to developing promising pharmaceutical delivery systems to setback the restrictions related to conventional cancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Nanocomposite Films for Food Packaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Cancer statistics, 2022
2. Cancer
3. Cancer statistics for the year 2020: an overview10.1002/ijc.33588 ↗
4. Sodium alginate based drug delivery in management of breast cancer10.1016/j.carbpol.2022.119689 ↗
5. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting10.1016/j.ijpharm.2019.05.042 ↗
6. Targeting metastatic cancer10.1038/s41591-020-01195-4 ↗
7. Genetic and non-genetic mechanisms underlying cancer evolution10.3390/cancers13061380 ↗
8. Non-genetic mechanisms of therapeutic resistance in cancer10.1038/s41568-020-00302-4 ↗
9. Nanomaterials for cancer therapy: current progress and perspectives10.1186/s13045-021-01096-0 ↗
10. Hallmarks of cancer: new dimensions10.1158/2159-8290.CD-21-1059 ↗
11. Advancing to the era of cancer immunotherapy10.1002/cac2.12178 ↗
12. Cancer
13. Cancer etiology: a metabolic disease originating from life’s major evolutionary transition?10.1155/2019/7831952 ↗
14. Dendrimer platform against prostate cancer: recent update on new horizon of treatment
15. Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer
16. Small molecules, big impact: 20 years of targeted therapy in oncology10.1016/S0140-6736(20)30164-1 ↗
17. Nanoemulsions as effective carriers for the treatment of lung cancer
18. Exploring the role of mesoporous silica nanoparticle in the development of novel drug delivery systems10.1007/s13346-021-00935-4 ↗
19. Using chitosan or chitosan derivatives in cancer therapy10.3390/polysaccharides2040048 ↗
20. Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-1210.1016/j.biomaterials.2012.02.014 ↗
21. Formulation and evaluation of hyaluronic acid-based mucoadhesive self nanoemulsifying drug delivery system (SNEDDS) of tamoxifen for targeting breast cancer10.1016/j.ijbiomac.2020.02.275 ↗
22. Macrophage-targeted sonodynamic/photothermal synergistic therapy for preventing atherosclerotic plaque progression using CuS/tio2heterostructured nanosheets10.1021/acsnano.2c02177 ↗
23. The association of frailty with outcomes after cancer surgery: a systematic review and meta-analysis10.1245/s10434-021-11321-2 ↗
24. Chitosan-based nanodelivery systems for cancer therapy: recent advances10.1016/j.carbpol.2021.118464 ↗
25. Nanomaterials in combating cancer: therapeutic applications and developments10.1016/j.nano.2013.07.001 ↗
26. A review on nano-based drug delivery system for cancer chemoimmunotherapy
27. Functionalized chitosan as a promising platform for cancer immunotherapy: a review10.1016/j.carbpol.2022.119452 ↗
28. A review of cancer immunotherapy: from the past, to the present, to the future10.3747/co.27.5223 ↗
29. Augmenting the synergies of chemotherapy and immunotherapy through drug delivery10.1016/j.actbio.2019.02.012 ↗
30. Detachable nanoparticle-enhanced chemoimmunotherapy based on precise killing of tumor seeds and normalizing the growing soil strategy10.1021/acs.nanolett.0c01415 ↗
31. Chitosan-based drug delivery systems10.1016/j.ejpb.2012.04.007 ↗
32. Advancement on modification of chitosan biopolymer and its potential applications10.1016/j.ijbiomac.2020.02.196 ↗
33. Advancement of chitin and chitosan as promising biomaterials10.1016/j.jscs.2022.101561 ↗
34. Chitin and chitosan: structure, properties and applications in biomedical engineering10.1007/s10924-016-0865-5 ↗
35. Mechanism and application of chitosan and its derivatives in promoting permeation in transdermal drug delivery systems: a review10.3390/ph15040459 ↗
36. Chitosan-based injectable in situ forming hydrogels containing dopamine-reduced graphene oxide and resveratrol for breast cancer chemo-photothermal therapy10.1016/j.bej.2022.108529 ↗
37. Prabaharan M, Mano JF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv. n.d.;12:41–57. doi:https://doi.org/10.1080/10717540590889781.10.1080/10717540590889781 ↗
38. A novel use of chitosan as a hypocholesterolemic agent in rats10.1093/ajcn/33.4.787 ↗
39. Proapoptotic effect of a dietary supplement: water soluble chitosan activates caspase-8 and modulating death receptor expression10.2133/dmpk.19.76 ↗
40. In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells
41. Chitosan prevents the development of AOM-induced aberrant crypt foci in mice and suppressed the proliferation of AGS cells by inhibiting DNA synthesis10.1002/jcb.21152 ↗
42. Chitosan exerts anticancer activity through induction of apoptosis and cell cycle arrest in oral cancer cells10.2334/josnusd.56.119 ↗
43. Anticancer properties of chitosan against osteosarcoma, breast cancer and cervical cancer cell lines
44. Applications of chitin and chitosan nanofibers in bone regenerative engineering10.1016/j.carbpol.2019.115658 ↗
45. Chitosan and its derivatives: synthesis, biotechnological applications, and future challenges10.1007/s00253-018-9550-z ↗
46. Chitosan-based drug delivery systems: from synthesis strategy to osteomyelitis treatment – a review10.1016/j.carbpol.2020.117063 ↗
47. Chitosan and its derivatives for drug delivery
48. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery10.3390/pharmaceutics9040053 ↗
49. Cancer-nano-interaction: from cellular uptake to mechanobiological responses10.3390/ijms22179587 ↗
50. Effects of the molecular weight and the degree of deacetylation of chitosan oligosaccharides on antitumor activity10.3390/ijms12010266 ↗
51. Microbial polysaccharides: an emerging family of natural biomaterials for cancer therapy and diagnostics10.1016/j.semcancer.2021.05.021 ↗
52. In vivo toxicity studies of chitosan-coated cobalt ferrite nanocomplex for its application as MRI contrast dye10.1021/acsabm.0c01069 ↗
53. Anticancer activity of chitosan, chitosan derivatives, and their mechanism of action10.1155/2018/2952085 ↗
54. Antitumor effects of various low-molecular-weight chitosans are due to increased natural killer activity of intestinal intraepithelial lymphocytes in sarcoma 180-bearing mice10.1093/jn/134.4.945 ↗
55. Chitosan as anticancer compound and nanoparticulate matrix for cancer therapeutics
56. A new chitosan-thymine conjugate: synthesis, characterization and biological activity10.1016/j.ijbiomac.2012.01.015 ↗
57. Antimicrobial and antitumor activities of 1,2,4-triazoles/polypyrrole chitosan core shell nanoparticles10.1002/poc.3702 ↗
58. Carboxymethyl chitosan represses tumor angiogenesis in vitro and in vivo10.1016/j.carbpol.2015.04.040 ↗
59. Chitosan derivatives inhibit cell proliferation and induce apoptosis in breast cancer cells
60. Strong electronic charge as an important factor for anticancer activity of chitooligosaccharides (COS)10.1016/j.lfs.2005.09.039 ↗
61. Recent advances in chitosan and its derivatives in cancer treatment10.3389/fphar.2022.888740 ↗
62. Chitosan modification and pharmaceutical/biomedical applications10.3390/md8071962 ↗
63. Polysaccharide based nano/microformulation: an effective and versatile oral drug delivery system
64. Singh · 2015 · vol. 1
65. Molecular-weight-dependent toxic effects of chitosans on the human keratinocyte cell line HaCaT10.1159/000276996 ↗
66. The potential of chitosan in nanomedicine: an overview of the cytotoxicity of chitosan based nanoparticles10.3389/fphar.2022.880377 ↗
67. Hyaluronic acid in inflammation and tissue regeneration
68. Hyaluronic acid: a review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies10.1016/j.ijbiomac.2019.11.066 ↗
69. Hyaluronic acid-mediated drug delivery system targeting for inflammatory skin diseases: a mini review10.3389/fphar.2020.01105 ↗
70. Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system10.1016/j.jconrel.2018.04.015 ↗
71. Hyaluronic acid: molecular mechanisms and therapeutic trajectory10.3389/fvets.2019.00192 ↗
72. Size matters: molecular weight specificity of hyaluronan effects in cell biology10.1155/2015/563818 ↗
73. Hyaluronan as tunable drug delivery system10.1016/j.addr.2019.08.006 ↗
74. Hyaluronidases: their genomics, structures, and mechanisms of action10.1021/cr050247k ↗
75. Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD4410.1186/s12951-016-0245-2 ↗
76. Hyaluronic acid-based biomaterials: a versatile and smart approach to tissue regeneration and treating traumatic, surgical, and chronic wounds10.1080/15583724.2017.1315433 ↗
77. CD44 variant 6 as a predictive biomarker for distant metastasis in patients with epithelial ovarian cancer10.1097/AOG.0000000000001420 ↗
78. New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy
79. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation10.1172/JCI200112455 ↗
80. Hyaluroan-regulated lymphatic permeability through S1P receptors is crucial for cancer metastasis10.1007/s12032-014-0381-1 ↗
81. Rheostatic signaling by CD44 and hyaluronan10.1016/j.cellsig.2009.01.024 ↗
82. Hyaluronan regulates PPARγ and inflammatory responses in IL-1β-stimulated human chondrosarcoma cells, a model for osteoarthritis10.1016/j.carbpol.2012.06.071 ↗
83. Cancer microenviroment and inflammation: role of hyaluronan10.3389/fimmu.2015.00169 ↗
84. NF-kB and caspases are involved in the hyaluronan and chondroitin-4- sulphate-exerted antioxidant effect in fibroblast cultures exposed to oxidative stress10.1002/jat.1302 ↗
85. Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer10.1016/j.colsurfb.2011.10.029 ↗
86. Hyaluronic acid bioconjugates for the delivery of bioactive molecules10.3390/polym6020346 ↗
87. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives10.1016/S0168-3659(97)00242-3 ↗
88. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine10.3109/1061186X.2015.1052072 ↗
89. Microtubules as a target for anticancer drugs10.1038/nrc1317 ↗
90. Hyaluronic acid-coated nanomedicine for targeted cancer therapy10.3390/pharmaceutics11070301 ↗
91. Hyaluronic acid-based nanomaterials for cancer therapy10.3390/polym10101133 ↗
92. In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation10.1016/j.ijpharm.2019.01.012 ↗
93. Chitosan nanoparticles-based ionic gelation method: a promising candidate for plant disease management10.3390/polym14040662 ↗
94. Ionotropic gelation method in the synthesis of nanoparticles/microparticles for biomedical purposes10.1002/pi.5970 ↗
95. Chitosan-based agronanochemicals as a sustainable alternative in crop protection10.3390/molecules25071611 ↗
96. Preparation of alginate and chitosan nanoparticles using a new reverse micellar system10.1007/s13726-011-0010-1 ↗
97. Chitosan nanoparticles: a survey of preparation methods10.3109/1061186X.2011.654121 ↗
98. The different ways to chitosan/hyaluronic acid nanoparticles: templated vs direct complexation. Influence of particle preparation on morphology, cell uptake and silencing efficiency10.3762/bjnano.10.250 ↗
99. Nanoformulation of antioxidant supplements
100. Antitumor evaluation of carboxymethyl chitosan based norcantharidin conjugates against gastric cancer as novel polymer therapeutics10.1016/j.ijbiomac.2019.05.216 ↗